Professor of Oncology, Johns Hopkins University School of Medicine; Co-Director, Breast Cancer Program
Hematology
Dr. Vered Stearns, MD
|
|
Give Review
Doctor Vered Stearns, MD is an expert in the field of Hematology. He attended Rutgers Robert Wood Johnson Medical School. Rutgers Robert Wood Johnson Medical School is ranked 74 in research and 67 in primary care medicine He received awards:"CMS Meaningful Use Stage 1 Certification". Vered Stearns is also a published physician. He has 99 paper published. The most recent paper is: Does tamoxifen cause cancer in humans? Doctor Vered Stearns, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
- Diagnostic accuracy of sentinel node identification is maintained with the addition of local lidocaine and subareolar radioactive colloid injection.
- TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative Systemic therapy in human epidermal growth factor receptor 2-negative primary operab...
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer.
- Neoadjuvant Chemotherapy and Short-term Morbidity in Patients Undergoing Mastectomy With and Without Breast Reconstruction.
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast Cancer brain metastases.
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer.
- Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial Cancers.
- Patient-reported outcomes in women with breast Cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reduc...
- Reply to K.I. Pritchard.
- A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung Cancers.
- Aromatase inhibitor-induced modulation of Breast density: clinical and genetic effects.
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer.
- Statins and Breast Cancer: Future Directions in Chemoprevention.
- Postmenopausal hormone receptor-positive advanced breast Cancer.
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast Cancer.
- Predictors of recovery of ovarian function during aromatase inhibitor therapy.
- Treatment-Emergent Effects May Predict Benefit From Endocrine Therapy.
- Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast Cancer.
- Current approaches for neoadjuvant chemotherapy in breast Cancer.
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial.
- A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast Cancer patients taking aromat...
- Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast Cancer.
- Intraductal Administration of a Polymeric Nanoparticle Formulation of Curcumin (NanoCurc) Significantly Attenuates Incidence of Mammary Tumors in a Rodent Chemical Car...
- Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast Cancer.
- Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast Cancer.
- Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast Cancer.
- Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole.
- Prospective characterization of musculoskeletal symptoms in early stage breast Cancer patients treated with aromatase inhibitors.
- American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast Cancer.
- Personalized tamoxifen: a step closer but miles to go.
- Preclinical and clinical evaluation of intraductally administered agents in early breast Cancer.
- Comparison of breast Cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast Cancer.
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast Cancer.
- Effect of simvastatin on the pharmacokinetics of anastrozole.
- A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3? Phosphorylation Site and Is Associated with Altered Tamoxifen Response in Bone.
- Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results.
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast Cancer: new perspectives 2006.
- Plasma letrozole concentrations in postmenopausal women with breast Cancer are associated with CYP2A6 genetic variants, body mass index, and age.
- Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
- Pharmacogenetics in the treatment of breast Cancer.
- Modeling hot flushes and quality of life in breast Cancer survivors.
- Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast Cancer patients.
- Practical clinical guidelines for assessing and managing menopausal symptoms after breast Cancer.
- Prognostic factors in breast Cancer: current and new predictors of metastasis.
- Does tamoxifen cause Cancer in humans?
- Circulating tumor markers in breast Cancer: accepted utilities and novel prospects.
- A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast Cancer survivors.
- New prognostic factors for breast Cancer recurrence.
- When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast Cancer.
- The Role of c-erbB-2 as a predictive factor in breast Cancer.
- Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
- Déjàvu for breast Cancer two?
- Management of hot flashes in breast Cancer survivors and men with prostate Cancer.
- New therapeutic approaches for hot flashes in women.
- Can hypnosis reduce hot flashes in breast Cancer survivors? A literature review.
- Multiparametric and multinuclear magnetic resonance imaging of human breast Cancer: current applications.
- A pilot surrogate end point biomarker trial of perillyl alcohol in Breast neoplasia.
- A pilot study to establish a clinical model to perform phase II studies of breast Cancer chemopreventive agents in women at high risk with biomarkers as surrogate endp...
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast Cancer treatment.
- CYP2D6 genotype and tamoxifen response.
- Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.
- Centrally active nonhormonal hot flash therapies.
- Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms.
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast Cancer: an update.
- Lipophilic statins merit additional study for breast Cancer chemoprevention.
- Myeloid toxicity in breast Cancer patients receiving adjuvant chemotherapy with pegfilgrastim support.
- Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies.
- Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic Breast carcinoma on FDG PET/CT.
- Disease-free survival was greater with letrozole than tamoxifen in postmenopausal women with early breast Cancer.
- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast Cancer treatment.
- Chemoprevention of breast Cancer: tamoxifen, raloxifene, and beyond.
- More choices, more questions: weighing the options for treating hot flashes.
- Breast Cancer treatment and ovarian failure: risk factors and emerging genetic determinants.
- Pilot evaluation of hypnosis for the treatment of hot flashes in breast Cancer survivors.
- Raloxifene and tamoxifen had similar efficacy for preventing invasive breast Cancer in women at increased risk.
- Role of CYP2D6 testing in selection of endocrine therapy for breast Cancer.
- Elevated tissue sodium concentration in malignant Breast lesions detected with non-invasive 23Na MRI.
- Clinical update: new treatments for hot flushes.
- Cooling off hot flashes.
- Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast Cancer may reliably represent the axilla except for inflammatory breast Cancer.
- Development and validation of a method for using Breast core needle biopsies for gene expression microarray analyses.
- Epigenetic regulation as a new target for breast Cancer therapy.
- Extended adjuvant therapy for breast Cancer--how much is enough?
- Chemotherapeutic Strategies for advanced breast Cancer.
- Adjuvant aromatase inhibitors and emerging quality-of-life considerations.
- A diet low in fat and high in vegetables, fruit, and fiber following breast Cancer treatment did not reduce new breast Cancer events.
- A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
- Symptoms, supportive care needs, and function in Cancer patients: how are they related?
- Randomized trial of a hypnosis intervention for treatment of hot flashes among breast Cancer survivors.
- Drug interactions and pharmacogenomics in the treatment of breast Cancer and depression.
- Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
- Pharmacogenetics and breast Cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
- Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
Schools
University of Medicine And Dentistry of New Jersey Robert Wood Johnson Medical School
Georgetown University Hospital
Lombardi Cancer Center Georgetown University Hospital
Conditions Treated
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice Advantage
- Blue Choice Network POS
- Blue Preferred PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Southern Health PPO
- Coventry Health Care of Delaware PPO
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Golden Rule
- Choice Care PPO
- Kaiser Permanente
- Maryland Physicians Care
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Georgetown University Hospital -
Rutgers Robert Wood Johnson Medical School
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1861420945 | |
| NPPES Provider LastName | STEARNS | |
| NPPES Provider FirstName | VERED | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 70.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861420945 |
| Last Name Of The Provider | STEARNS |
| First Name Of The Provider | VERED |
| View All |
Similar Doctors
|
|
Dr. Amy E. Dezern, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanford A. Stass, MD |
|
|
Dr. Michael J. Purtell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alison R. Moliterno, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy K. Bernstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy S. Kimball, MD |
|
|
Dr. Christopher J. Melani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Milos Miljkovic, MD |
|
|
Laxmi H. Iyer, MB BS |